Regeneron Pharmaceuticals Aktie News

Regeneron Pharmaceuticals, Inc. ( REGN ) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline November 10, 2025 8:30 AM EST Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis George Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-Chairman L. Sirulnik - Senior Vice President of Clinical Development Uni...

ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

TARRYTOWN, N.Y., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

Novo Nordisk has several catalysts that could jolt its sluggish stock over the next few years. Regeneron is handling biosimilar competition well while mitigating the threat with new launches.

Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions

Regeneron Pharmaceuticals, Inc. delivered a strong Q3 earnings beat, driven by Dupixent growth, despite ongoing Eylea sales declines and manufacturing setbacks. REGN's future growth is anchored by Dupixent's expanding indications, a robust late-stage pipeline, and improving Libtayo performance, offsetting Eylea's decline. Management's financial discipline, $7B in manufacturing investments, and ...

Regeneron Pharmaceuticals, Inc. beat Q3 revenue and EPS expectations, and it appears investors are finally embracing the fact the Eylea franchise is no longer a growth product. Eylea franchise faces ongoing revenue declines, but market share losses have stabilized and regulatory issues for Eylea HD should be addressed in 2026. Dupixent collaboration profits with Sanofi are set to accelerate, su...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Leonard Schleifer - Co-Founder, President, CEO & Co-Chairman George Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-Chairman Marion McCourt - Executive Vice President of Commercial ...